This study reveals a significantly higher incidence of ALK alterations among Hispanic patients with NSCLC at a large academic center in Los Angeles, California, with a prevalence of 12.76% compared with 5.36% in non-Hispanic patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.